Phase 3 randomized double-blind placebo-controlled trial of subcutaneous depigmented polymerized olive pollen extract immunotherapy in olive pollen allergy

Phase 3, randomised, double-blind trial of depigmented polymerized olea europaea pollen extract in olive pollen allergy, allergic rhinoconjunctivitis (ARC) and asthma (2 arms), sponsored by LETI Pharma. Primary endpoints: Symptom score during pollen season and Medication consumption. Started May 2007; status: active.